8-K: BrainStorm Cell Therapeutics Announces 2023 Financial Results and Provides Update on NurOwn Program

BrainStorm Cell Therapeutics reported its full year 2023 financial results and provided an update on its NurOwn program, including plans for a confirmatory Phase 3b trial.

Summary

• BrainStorm Cell Therapeutics announced its financial results for the year ended December 31, 2023, and provided a corporate update.
• The company's priority for 2024 is to advance a confirmatory Phase 3b trial for NurOwn, aimed at supporting a new Biologics License Application.
• BrainStorm is working closely with the FDA to agree on a Special Protocol Assessment (SPA) for the Phase 3b trial.
• The company believes an SPA will significantly reduce the regulatory risks associated with the program.
• BrainStorm submitted an SPA request to the FDA in February 2024 for the Phase 3b study of NurOwn.
• The FDA is expected to respond to the SPA request soon, as the 45-day review cycle is approaching.
• The proposed design for the Phase 3b trial was presented at the MDA Clinical and Scientific Conference in March 2024.
• In October 2023, Brainstorm withdrew its Biological License Application (BLA) for NurOwn in ALS, following an FDA advisory committee meeting in September 2023.
• The company underwent a strategic realignment in October 2023, which included a reduction in headcount of approximately 30 percent.
• Cash, cash equivalents, and restricted cash totaled $1.45 million as of December 31, 2023, compared to $3 million at the end of 2022.
• Research and development expenses were approximately $10.8 million for 2023, down from $14 million in 2022.
• General and administrative expenses were approximately $10.7 million in 2023, compared to $10.9 million in 2022.
• The net loss for 2023 was $17.2 million, an improvement from the $24.3 million loss in 2022.
• Net loss per share was $0.40 for 2023, compared to $0.66 in 2022.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in planning a new Phase 3b trial and cost reductions, the low cash position, BLA withdrawal, and continued losses temper the positive aspects. The overall sentiment is cautiously negative.

Positives

• The company is actively pursuing a confirmatory Phase 3b trial for NurOwn, which is a positive step towards potential regulatory approval.
• The submission of the SPA request to the FDA indicates progress in the regulatory process.
• The reduction in research and development expenses and overall net loss suggests improved cost management.
• The company is focused on a clear path forward for NurOwn in ALS.

Negatives

• The company's cash position has decreased significantly to $1.45 million.
• The withdrawal of the BLA for NurOwn in ALS is a setback.
• The company had a net loss of $17.2 million for the year.

Risks

• The company's ability to secure a Special Protocol Assessment (SPA) with the FDA is critical for the Phase 3b trial.
• There is a risk that the FDA may not agree with the proposed study design.
• The company's low cash position raises concerns about its ability to fund future operations and clinical trials.
• The company is dependent on the success of the NurOwn program for its future.

Future Outlook

BrainStorm's priority for 2024 is to move forward with a confirmatory Phase 3b trial for NurOwn, with the goal of obtaining a Special Protocol Assessment (SPA) from the FDA. The company is committed to this rigorous planning process and believes that, if approved, NurOwn has the potential to be a valuable treatment option for ALS patients.

Management Comments

• Chaim Lebovits, President and Chief Executive Officer of BrainStorm, stated that the company's priority for 2024 is to move forward with a confirmatory Phase 3b trial for NurOwn.
• Chaim Lebovits also mentioned that they have been working closely with the FDA with the goal of agreeing on a Special Protocol Assessment (SPA).
• Stacy Lindborg, Ph.D., co-CEO of BrainStorm, commented that the planned Phase 3b trial will be conducted with the highest standards of scientific excellence and integrity.

Industry Context

The announcement comes as the biotechnology industry continues to focus on developing treatments for neurodegenerative diseases like ALS. BrainStorm's efforts to advance NurOwn are part of this broader trend, with the company seeking to address a significant unmet medical need. The regulatory pathway for cell therapies is complex, and the company's interactions with the FDA are critical for its success.

Comparison to Industry Standards

• Brainstorm's cash position of $1.45 million is low compared to other biotech companies at a similar stage of clinical development, which typically have tens of millions in cash reserves.
• The reduction in R&D expenses is a common strategy for companies facing financial constraints, but it could also slow down the pace of development.
• The net loss of $17.2 million is significant, but the improvement from the previous year is a positive sign.
• The withdrawal of the BLA is a major setback, as most companies in this space would have a BLA as a key milestone.
• The focus on a new Phase 3b trial is a common approach after a regulatory setback, but it adds time and cost to the development process.
• Companies like Biogen and Amylyx Pharmaceuticals have recently received FDA approval for ALS treatments, setting a high bar for efficacy and safety.

Stakeholder Impact

• Shareholders may be concerned about the company's low cash position and the withdrawal of the BLA.
• Employees may be affected by the strategic realignment and headcount reduction.
• ALS patients and their families may be hopeful about the potential of NurOwn but also concerned about the delays in the regulatory process.
• Creditors may be concerned about the company's financial stability.

Next Steps

• The company will continue to work with the FDA to secure a Special Protocol Assessment (SPA) for the Phase 3b trial.
• BrainStorm will conduct a confirmatory Phase 3b trial for NurOwn.
• The company will host a conference call in early April 2024 to discuss plans for NurOwn.
• The company expects a response from the FDA on the SPA request soon.

Key Dates

Keywords

NurOwn, ALS, Phase 3b trial, Special Protocol Assessment, SPA, FDA, Biologics License Application, BLA, Cell Therapy, Neurodegenerative Diseases, Stem Cell Therapeutics